Navigation Links
Diatos Announces Positive Clinical Results for its DTS-201,Doxorubicin Prodrug Program

PARIS--(BUSINESS WIRE)--Jun 4, 2007 - Diatos SA, an international biopharmaceutical company focusing on the research, development and commercialization of targeted anti-cancer drugs, today announced that they presented data from a Phase I clinical trial of their anti-cancer compound, DTS-201, at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA.

DTS-201 is a doxorubicin prodrug developed for the targeted treatment of several solid cancers, including chemo-resistant tumors. The product is activated by enzymes specific to the tumor environment. During its Phase I clinical trial, DTS-201 was shown to be well tolerated and able to deliver high doses of free doxorubicin in humans.

The purpose of the DTS-201 Phase I clinical study is to assess the product's Maximum Tolerated Dose (MTD), safety profile and pharmacokinetic profile in patients with advanced or metastatic solid tumors. In a poster presentation entitled "Results of a Phase I study of DTS-201, a peptidic prodrug of doxorubicin in patients with solid tumors (Abstract # 2547)", researchers concluded that:

-- DTS-201 was well tolerated by twenty-five cancer patients treated with doses of up to 400 mg/m2 every three weeks. This corresponds to 3.75 times the standard dose of doxorubicin;

-- DTS-201 was safe and well tolerated at cumulative doses of up to 2750 mg/m2;

-- Evidence of clinical efficacy was observed: two patients showed partial responses and three patients with chemo-resistant tumors showed disease stabilisation;

-- The recommended dose for Phase II clinical trials is 400 mg/m2.

The high levels of tolerance to the product and positive clinical responses observed during this Phase I trial strongly support an assessment of the efficacy of DTS-201 in a Phase II study.

"DTS-201 is a safe and active compound which allowed delivery of a high dose of doxorubicin with out any unexpected side effects," stated Jean-Pierre Delord, M.D., principal investigator from the anti-cancer center Claudius Regaud Institute in Toulouse, France. "In particular, no severe toxicity has been observed even after the administration of six cycles of the agent in this Phase I trial. Furthermore, we have observed some encouraging activity in normally chemo-resistant cancers."

DTS-201 was initially discovered by Pr Andre Trouet and his team at the Universite Catholique de Louvain, Belgium, and exclusive European rights were in-licensed from Medarex Inc. in April 2003 as a preclinical compound.

President and CEO of Diatos John Tchelingerian, Ph.D, added: "I am satisfied that Diatos continues to make substantial progress in its clinical development programs based on novel, targeted anti-cancer chemotherapies. The positive results from our Phase I study with DTS-201, particularly the encouraging signs of improved efficacy versus standard doxorubicin treatment, represent a significant milestone in the development of our product. Diatos is poised to initiate a Phase II study for DTS-201 in Europe soon, advancing what we believe is a next generation anthracycline for the benefit of cancer patients."

Notes to Editors:

About DTS-201

DTS-201 consists of doxorubicin, a marketed cytotoxic agent effective against a wide variety of solid tumors, conjugated to a proprietary peptide. The product was discovered in 1996 by Pr Andre Trouet and his team at the Universite Catholique de Louvain, Belgium and in-licensed from Medarex Inc in April 2003. DTS-201 is also known as Super-Leu-Dox or CPI-0004Na in the USA.

DTS-201 is a prodrug designed to preferentially deliver doxorubicin to tumors as opposed to normal tissues. It consists of the tetrapeptide N-succinyl-(beta)-alanyl-L-leucyl-L-alanyl-L-leucine covalently linked to the aminoglycoside portion of doxorubicin.

Peptide-based targeting of tumors is an attractive approach f or tumor selective drug delivery. The DTS-201 concept is based on the inactivation of doxorubicin by the coupling of a tetrapeptidic sequence that prevents cellular uptake. DTS-201 is stable in blood but cleavable by some specific peptidases present in the tumor environment. Preclinical studies have demonstrated that DTS-201 was less toxic in rodents and dogs than free doxorubicin and significantly more effective in a wide panel of human tumor xenograft models.

Reactivation of doxorubicin occurs extracellularly in the tumor through enzymatic cleavage of the peptide by at least two enzymes: CD10 (Neprilysin / CALLA) and Thimet Oligopeptidase (TOP). They produce two intermediate metabolites Ala-Leu-Dox and Leu-Dox which enter stromal and tumor cells and are converted into free doxorubicin.

About Diatos

Diatos is a biopharmaceutical company dedicated to the research, development and commercialization of innovative anti-cancer drugs with enhanced tumor targeting or improved biodistribution. Diatos is expanding its portfolio of drug candidates with new compounds that utilize its Vectocell(R) delivery technology or its Tumor-Selective Prodrug (TSP) technology as well as with in-licensed candidate and marketed cancer therapies. Diatos is headquartered in Paris, France and operates subsidiaries in Belgium and the United States of America.

About Diatos' Portfolio

-- DaunoXome(R), a liposomal formulation of widely used cancer drug daunorubicin, improves the biodistribution of daunorubicin and fosters its sustained release in the blood, which potentially allows the administration of higher doses than with non-liposomal formulations. DaunoXome is marketed in Kaposi's sarcoma and under review for the treatment of acute leukaemia in Europe. DaunoXome was in-licensed from Gilead Sciences, Inc. (NASDAQ: GILD).

-- DTS-301, a paclitaxel depot formulation in the polymer gel ReGel(R), releases paclitaxel, a widely used cancer drug, directly to the tumor site, avoiding systemic side effects. DTS-301 is in Phase II clinical studies and was in-licensed from Protherics PLC (LSE: PTI / NASDAQ: PTIL).

-- DTS-201, a doxorubicin prodrug, increases the concentration of doxorubicin, a widely used cancer drug, at the tumor site by means of a reactivation mechanism specific to the tumor environment. DTS-201 has completed Phase I clinical studies in Belgium and France in Q2-07. Exclusive European rights for DTS-201 were in-licensed from Medarex Inc.

-- DTS-108 is a prodrug of SN-38, the active metabolite of the widely-used cancer drug irinotecan, and is based on Diatos' Vectocell(R) technology. DTS-108 aims to increase the efficacy of SN-38 while reducing the toxic effects of irinotecan. DTS-108 is in preclinical development.

For more information on Diatos, please visit www.diatos.com.

The Diatos logo and Vectocell(R) are registered trademarks of Diatos SA.

Contact

Diatos SA
General enquiries
Dr John Tchelingerian, PhD, President & CEO
c/o Virginie Leplat
Director of Human Resources & Administration
Tel.: +33 (0)1 53 80 93 80
vleplat@diatos.com
or
c/o Guillaume Dussert, Associate BD & Marketing Manager
Tel.: +33-(0)1 53 80 93 83
gdussert@diatos.com
or
Medical enquiries
Dr Jamal Gasmi, MD, MSc
Chief Medical Officer
Head of Clinical Development & Regulatory Affairs
Tel.: +33 (0)1 53 80 93 53
jgasmi@diatos.com
or
Press contacts
Northbank Communications
Justine Lamond, +44 (0)20 7268 3242
diatos@northbankcommunications.com


'"/>




Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... June 5, 2017 The Cincinnati ... Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded a ... . Results are based on an employee survey ... health and workplace improvement. The survey measures several aspects of ... ...
(Date:5/30/2017)... , May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... data solutions, today announced that it will be presenting at the ... 8:00 AM PT. Erez Raphael , CEO, of DarioHealth will ... conference will be held on June 6th & 7th, 2017 at ... in the small / micro-cap space. ...
(Date:5/26/2017)... 25, 2017  In response to the opioid epidemic ... Relief is working with Pfizer to make up to ... cost to community health centers, free and charitable clinics, ... "Pfizer has a long-standing commitment to improving ... patient safety through educational activities," said Caroline Roan ...
Breaking Medicine Technology:
(Date:6/27/2017)... Simi Valley, CA (PRWEB) , ... June 27, 2017 , ... ... deployed since 2001 suffer from PTSD. Yet less than 20% will receive adequate care ... of those with PTSD won't receive any care at all. And left untreated, veterans ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... Antoine Dental Center is now ... standard in tooth replacement and act as a support for prosthetic teeth, such as crowns, ... the existing bone and becomes a sturdy, lasting new root for the tooth. , ...
(Date:6/26/2017)... Lake Tahoe, CA (PRWEB) , ... June 26, 2017 , ... ... seeking 10,000 qualified mental health professionals in every state across the country to join ... an easy and rewarding way for therapists to reach a substantially greater number of ...
(Date:6/25/2017)... ... , ... Create a feel-good lyric music video in Final Cut Pro X with ProLyric from ... write in the lyrics to any song. ProLyric flies in the text for each section ... can be added modularly for optimal control. ProLyric makes editing any music video or text-based ...
(Date:6/25/2017)... , ... June 25, 2017 , ... June is Men’s Health Month and ... most common cancer among men in the U.S. and the third most common cause of ... estimated that one man in seven will be diagnosed with prostate cancer during his lifetime. ...
Breaking Medicine News(10 mins):